In silico study of ligand binding site of toll-like receptor 5

Savar, Nastaran Sadat; Bouzari, Saeid

In silico study of ligand binding site of toll-like receptor 5

Authors

¹ Department of Molecular Biology, Pasteur Institute of Iran; Department of Biology, Science and Research Branch, Islamic Azad university, Tehran, Iran

² Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran

Abstract

Background: Toll-like receptor-5 (TLR-5) is a member of TLRs family and responsible for bacterial flagellin recognition. The activation of TLR-5 with flagellin leads to initiation of signaling cascades, which in turn results in transcription of pro-inflammatory cytokines. Regarding the critical role of TLR-5 agonists and antagonists in activation of innate immune responses, an increasing number of studies have focused on their therapeutic applications in drug and vaccine design. In this study, to identify the most critical region and residues of TLR-5 for interaction with flagellin, different truncated forms of TLR-5 were designed and subjected to protein-protein interaction studies.
Materials and Methods: The interactions of the full native TLR-5 and its truncated forms with bacterial flagellin (FliC) were evaluated using Hex docking server and molecular interaction analysis was performed using Dimplot analysis.
Results: According to our in silico results, truncated form C (an amino acid sequence containing residues 174-401 of TLR-5) has the most suitable interaction with FliC and seven amino acids within this region were found to be crucial for the interaction with flagellin.
Conclusions: These results provide new insights in to potential drug target sites of TLR-5, which may guide future TLR-5 targeting studies.

Keywords

References

1.	Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors. Nat Immunol 2010;11:373-84. [PUBMED]
2.	Akira S, Takeda K. toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511. [PUBMED]
3.	Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N, et al. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in toll-like receptor signaling. Proc Natl Acad Sci U S A 2004;101:15416-21.
4.	Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, et al. Interferon-alpha induction through toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004;5:1061-8. [PUBMED]
5.	Pandey S, Agrawal DK. Immunobiology of toll-like receptors: Emerging trends. Immunol Cell Biol 2006;84:333-41. [PUBMED]
6.	Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature 2001;410:1099-103. [PUBMED]
7.	Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 2003;170:5165-75. [PUBMED]
8.	Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008;26:201-14. [PUBMED]
9.	Vassilieva EV, Wang BZ, Vzorov AN, Wang L, Wang YC, Bozja J, et al. Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant. MBio 2011;2:e00328-10. [PUBMED]
10.	Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008;320:226-30. [PUBMED]
11.	O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009;61:177-97. [PUBMED]
12.	Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003;4:1247-53. [PUBMED]
13.	Jacchieri SG, Torquato R, Brentani RR. Structural study of binding of flagellin by toll-like receptor 5. J Bacteriol 2003;185:4243-7. [PUBMED]
14.	Mizel SB, West AP, Hantgan RR. Identification of a sequence in human toll-like receptor 5 required for the binding of gram-negative flagellin. J Biol Chem 2003;278:23624-9. [PUBMED]
15.	Andersen-Nissen E, Smith KD, Bonneau R, Strong RK, Aderem A. A conserved surface on toll-like receptor 5 recognizes bacterial flagellin. J Exp Med 2007;204:393-403. [PUBMED]
16.	Zhou K, Kanai R, Lee P, Wang HW, Modis Y. Toll-like receptor 5 forms asymmetric dimers in the absence of flagellin. J Struct Biol 2012;177:402-9.
17.	Guex N, Peitsch MC. Swiss-Model and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997;18:2714-23. [PUBMED]
18.	Ritchie DW, Venkatraman V. Ultra-fast FFT protein docking on graphics processors. Bioinformatics 2010;26:2398-405. [PUBMED]
19.	Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995;8:127-34. [PUBMED]
20.	Krishnan J, Lee G, Choi S. Drugs targeting toll-like receptors. Arch Pharm Res 2009;32:1485-502. [PUBMED]
21.	Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007;130:1071-82. [PUBMED]
22.	Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S, et al. Recognition of lipopeptide patterns by toll-like receptor 2-toll-like receptor 6 heterodimer. Immunity 2009;31:873-84. [PUBMED]
23.	Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008;320:379-81. [PUBMED]
24.	Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009;458:1191-5. [PUBMED]

Advanced Biomedical Research